Floatz logo

Adriamycin

Hand-Foot Syndrome

Swiss Cancer InstituteSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Hand-Foot Syndrome cohort.

Asset / SponsorPhaseRating
Mecobalamin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3B
Celecoxib
Affiliated Hospital of Qinghai University
Phase 3B
Indometacinum
National Taiwan University Hospital
Phase 2CCC
Tazarotene
Dana-Farber Cancer Institute
Phase 2CCC
Advicor Component Niacin
First People's Hospital of Hangzhou
Phase 2CCC

View all 11 →

Same molecule, other indications

Adriamycin is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →